Brief: Alvotech And Teva Announce Filing Acceptance Of U.S. Biologics License Application
18/02/2025 11:06
Feb 18 (Reuters) - Alvotech SA ALVO.O :
* ALVOTECH AND TEVA ANNOUNCE FILING ACCEPTANCE OF U.S.
BIOLOGICS
LICENSE APPLICATION FOR AVT06, A PROPOSED BIOSIMILAR TO EYLEA®
(AFLIBERCEPT)
* ALVOTECH SA - REGULATORY APPROVAL EXPECTED BY Q4 2025
* ALVOTECH SA - FDA ACCEPTS FOR REVIEW BLA FOR ALVOTECH'S
BIOSIMILAR TO EYLEA
Source text: ID:nGNX6fMNSN
Further company coverage: ALVO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alvotech SA
See all newsBrief: CMS Announces Selection Of Drugs For Third Cycle Of The Medicare Drug Price Negotiation Program
Brief: Alvotech and Teva Secure U.S. Settlement Date For AVT06
India's Dr Reddy's rises after EU marketing authorisation for osteoporosis biosimilar
Brief: UK High Court Rules In Favor Of Alvotech Paving Way For AVT06, Biosimilar To Eylea
U.S. STOCKS ON THE MOVE-Cummins, EPAM Systems, Qualcomm